+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Crigler Najjar Syndrome Drug"

Crigler-Najjar Syndrome - Pipeline Review, H2 2020 - Product Thumbnail Image

Crigler-Najjar Syndrome - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 39 Pages
  • Global
From
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Crigler Najjar Syndrome (CNS) is a rare genetic disorder that affects the body's ability to process bilirubin, a yellow pigment found in bile. As a result, bilirubin builds up in the blood, leading to jaundice and other serious health problems. Treatment for CNS typically involves the use of endocrine and metabolic disorder drugs. These drugs are designed to reduce the amount of bilirubin in the blood, allowing the body to process it more efficiently. In some cases, drugs may also be used to reduce the severity of symptoms associated with CNS. The market for endocrine and metabolic disorder drugs for CNS is relatively small, but it is growing. These drugs are typically used in combination with other treatments, such as phototherapy, to manage the condition. As the understanding of CNS increases, more drugs are being developed to treat the disorder. Some companies in the market include AbbVie, Amgen, and Novartis. These companies are developing drugs to treat CNS and other endocrine and metabolic disorders. Show Less Read more